Cell & gene therapy commercialization

End-to-end launch strategies for breakthrough therapies

SouthBridge Advisory specializes in commercializing advanced therapies, with proven expertise in navigating the complex landscape of cell & gene therapy (CGT). From India’s first CAR-T launch to global biologics scale-ups, we bring the execution know-how required to accelerate patient access while ensuring affordability and sustainability.

Our approach

Comprehensive launch strategy

Designing end-to-end roadmaps covering pricing, access, stakeholder engagement, and PSP development.

Market Access & Reimbursement Models

Creating sustainable frameworks tailored to LMICs, expanding patient reach while maintaining commercial viability.

Physician & Hospital Network Engagement

Activating treatment sites, building KOL advocacy, and ensuring clinical adoption through structured programs.

Patient Support Programs (PSPs)

Developing financial assistance, education, and treatment outcome–based initiatives to strengthen access pathways.

why partner with us?

Pioneers in CGT commercialization in emerging markets.
Direct experience in CAR-T, biologics, and biosimilars across 21 global markets.
Execution-first advisory that blends science, access, and real-world market insights.
Strong networks with KOLs, hospitals, and payers across oncology & haematology.

Testimonial

People like us, officially

Trusted by biopharma leaders, medical experts, and investors worldwide for delivering real-world commercialization success in advanced therapies.

SouthBridge’s deep understanding of pricing and access challenges in emerging markets was instrumental in the successful launch of our biologic. Their execution-first approach set them apart from other consultants.

Biopharma Executive Emerging Markets

The team at SouthBridge bridged the gap between science and market strategy. Their KOL engagement framework helped us build strong advocacy and accelerate adoption of our cell therapy

Medical Affairs Director Global CGT Company

SouthBridge’s due diligence and market insights gave us the confidence to invest in a groundbreaking gene therapy. Their practical expertise ensured we had a clear roadmap for commercialization.

Investor Healthcare VC Fund